The discussion meeting of clinical protocol for the allergic rhinitis phase II clinical trial of LP-003 (registration number CTR20231145), led by Professor Wang Xueyan from Beijing Shijitan Hospital affiliated with Capital Medical University, was successfully held in Beijing in March 2023. Researchers from various centers participating in this clinical study actively and deeply discussed the the clinical protocol.
Professor Wang Xueyan said, allergic rhinitis is a common chronic disease, affecting 10% -20% of the world's population. At the same time, the prevalence rate in China has risen from 11.1% in 2005 to 17.6%. After antihistamine and nasal spray hormone treatment, about 25% patients have limited efficacy. There is a big clinical need to R&D a new drug with better efficacy and better compliance.
LP-003 developed by Longbio is a new generation of anti-IgE antibody. Phase I clinical trial data showed that compared with the first generation of anti-IgE antibody omalizumab, it has better biological activity, higher affinity, and longer half-life, and is expected to become best-in-class. It is expected to bring clinical benefits to Allergic rhinitis patients in China and the world.
As the main inventor of the first generation of anti-IgE antibody, Omazumab, Dr. Sun Nai-chau, co-founder of Longbio, said that allergic rhinitis, chronic spontaneous urticaria and asthma are all IgE mediated diseases. The first generation of anti-IgE antibody have been widely used in clinical practice. Based on the understanding of the first and second generation of anti-IgE antibodies, the LP-003 developed by Longbio has stronger efficacy, better safety, lower dosage, and long efficacy.
We hope that LP-003 can be launched as soon as possible to find better treatment methods and solutions for patients with Allergic rhinitis, chronic spontaneous urticaria,, asthma and other allergic diseases, improving their quality of life and reduce their burden.
The centers participating in this clinical study also including Peking Union Medical College hospital, the third affiliated hospital of Peking University, Shengjing hospital, Tianjin people's hospital, the first affiliated hospital of Shanxi Medical University, the second affiliated hospital of Shanxi Medical University, the Ooriental hospital affiliated to Beijing University of Chinese Medicine and other 17 hospitals and clinical centers.
2023.05.11
